Faes Farma : Highlights from 2022 CMD
>2022 guidance in line with our estimates - For 2022 the company expects to achieve net sales of between € 422-437m, PBT of between € 100-104m and net profit of between € 89-93m, which compares with our net sales estimate of € 449m, PBT of € 108m and net profit of € 92m. Management believes that the strong performance for Bilastine’s internacional licences with recovered growth in Japan will compensate for the loss of patent protection of the molecule in Europe, whils...Faes Farma is engaged in the health care research, manufacture and sale of prescription pharmaceuticals, over-the-counter pharmaceuticals and fine chemicals, URGO bandages and dressings and LAZLO cosmetics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.